Department of Medicine I, Division of Gastroenterology, Ludwig Demling Endoscopy Center of Excellence, University Hospital of Erlangen, University Erlangen-Nürnberg, Erlangen, Germany.
Institute of Pathology, University Hospital of Erlangen, University Erlangen-Nürnberg, Erlangen, Germany.
Gastrointest Endosc. 2023 Jan;97(1):100-111.e1. doi: 10.1016/j.gie.2022.08.023. Epub 2022 Sep 2.
Apart from endoscopic healing as an established treatment goal in patients with inflammatory bowel disease (IBD), histologic remission is an emerging endpoint that might even better predict disease outcome, especially in ulcerative colitis (UC). Within this study, we aimed to evaluate whether endocytoscopy (EC) as an in vivo contact microscopy technology can accurately assess histologic inflammation and predict the further course of disease in UC patients.
Initially, a new and intuitive EC score reflecting the entire spectrum of microscopic disease activity in UC was consensually developed. Subsequently, this score was independently validated in 46 patients with UC who underwent close-meshed follow-up during which major adverse outcomes (MAOs; defined as disease flare, IBD-related hospitalization, IBD-related surgery, necessity for initiation or escalation therapy) were recorded. Results of EC grading of inflammatory activity were compared against 2 validated histologic scores in UC. Diagnostic performance of endoscopic remission under white-light endoscopy (Mayo Endoscopic Score and Ulcerative Colitis Endoscopic Index of Severity), EC, and histology were compared for the prediction of MAOs.
Endocytoscopic assessment of inflammatory activity in UC based on the newly developed ErLangen Endocytoscopy in ColiTis score showed strong correlation with histopathologic scoring (Robarts Histopathology Index, r = .70; Nancy Histologic Index, r = .73) and was superior to white-light endoscopy for grading of microscopic disease activity, with a sensitivity of 88%, specificity of 95.2%, and area under the curve of .916. Furthermore, EC exhibited a high interobserver agreement for in vivo grading of microscopic inflammation and was comparably accurate as histopathology for forecasting the occurrence of MAOs in UC.
Endocytoscopic grading of inflammatory activity along a newly developed scoring system enabled real-time histology in UC patients and better predicted clinical outcome in UC patients than endoscopic remission.
除了内镜愈合作为炎症性肠病(IBD)患者的既定治疗目标外,组织学缓解也是一个新兴的终点,它甚至可以更好地预测疾病的结果,特别是在溃疡性结肠炎(UC)中。在这项研究中,我们旨在评估内视镜细胞检查(EC)作为一种体内接触显微镜技术是否可以准确评估组织学炎症并预测 UC 患者的疾病进一步发展。
最初,开发了一种新的直观 EC 评分,反映了 UC 中整个微观疾病活动的范围。随后,在 46 例 UC 患者中对该评分进行了独立验证,这些患者在密切随访期间记录了主要不良事件(MAO;定义为疾病发作、与 IBD 相关的住院治疗、与 IBD 相关的手术、需要开始或升级治疗)。将 EC 炎症活动分级的结果与 2 种 UC 中经过验证的组织学评分进行了比较。比较了白光内镜(Mayo 内镜评分和溃疡性结肠炎内镜严重程度指数)、EC 和组织学下的内镜缓解对 MAO 的预测能力。
基于新开发的 Erlangen 大肠内视镜细胞检查的 UC 炎症活性的内视镜评估与组织病理学评分具有很强的相关性(罗巴特组织病理学指数,r =.70;南希组织学指数,r =.73),并且在微观疾病活动的分级方面优于白光内镜,其灵敏度为 88%,特异性为 95.2%,曲线下面积为.916。此外,EC 对体内微观炎症分级具有较高的观察者间一致性,并且与组织病理学相比,对 UC 中 MAO 的发生具有相当准确的预测能力。
沿新开发的评分系统对炎症活动进行 EC 分级,可以实时进行 UC 患者的组织学检查,并且比内镜缓解更好地预测 UC 患者的临床结局。